MedTrace Logo

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NCT05799157 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2025-05-08

No results posted yet for this study

Summary

This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris

Conditions

  • Verruca Vulgaris
  • Warts
  • Common Wart

Interventions

DRUG

VDMN-21 Patch Low Dose

Microneedle patch containing 125 mcg of active drug

DRUG

VDMN-21 Patch High Dose

Microneedle patch containing 250 mcg of active drug

DRUG

Vehicle Patch

Placebo microneedle patch containing no active drug (i.e., placebo)

Sponsors & Collaborators

  • Veradermics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2025-02-25
Completion
2025-02-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799157 on ClinicalTrials.gov